跳到正文
ISPE iSpeak 专家博客·· 16 天前AI 评分36

ISPE荷兰质量CoP在莱顿Bio Science Park首届研讨会正式启动,聚焦质量、文化与整合

Quality Unites: Building Community Beyond Compliance: Why Quality Needs Communities More Than Ever

AI 导读

ISPE荷兰质量实践社区(CoP)在莱顿Bio Science Park的BioTech Training Facility首届研讨会上正式启动,研讨会主题为“无孤岛的良好工作实践:质量、文化与整合”,由Hans de Koning主持,50余名质量专业人士参加。

正文 · 原文

The official launch of the Community, held during the inaugural seminar, “Good Working Practices Without Silos: Quality, Culture, and Integration” at the BioTech Training Facility in Leiden Bio Science Park, marked an important milestone—not only for the Netherlands Affiliate, but also for the wider conversation on the future of pharmaceutical quality.

Figure 1. A Symbolic Beginning: Opening a New Chapter for Quality professionals across the Netherlands (photo credit: Alexandra Belousova)


The pharmaceutical industry has never had more data, more technology, or more regulatory expectations than it does today. Yet one of the biggest challenges facing organizations remains surprisingly human:

How do we ensure that people, knowledge, and decisions remain connected?

In many organizations, quality, manufacturing, engineering, regulatory affairs, digital, leadership teams, and subject matter experts (SMEs) all work toward the same objective—delivering safe and effective medicines to patients. However, despite this shared purpose, expertise often remains fragmented across functions, departments, and reporting lines. The result is not necessarily a lack of competence. Rather, it is a lack of integration.

Different functions often approach the same objective from different perspectives. While one team may primarily see risks, another identifies opportunities, operational efficiency, business value, or regulatory implications. These complementary viewpoints are a strength, but without effective communication and integration they can unintentionally drive departments apart instead of bringing them together. True quality emerges when these diverse perspectives are connected, enabling balanced decisions that serve both patients and the organization.

This realization shaped discussions throughout the launch event. Chaired by Hans de Koning, Board Member of the ISPE Netherlands Quality CoP, the seminar brought together more than 50 quality professionals, leaders, and subject matter experts from organizations including Johnson & Johnson, Merck Sharp and Dohme, Teva, AstraZeneca, Astellas, HALIX, Bilthoven Biologicals, Progress, DSV, Yxion, TMC, Reckitt, MediaVision, and the Dutch Assocation of Research Quality Assurance to explore how collaboration, integration, and knowledge sharing can strengthen pharmaceutical quality.

While the event celebrated the official establishment and launch of the CoP to the wider public, it also demonstrated that many of the challenges facing quality are shared across organizations—and that addressing them requires communities, not just departments.

Figure 2. Group Photo at “Good Working Practices Without Silos: Quality, Culture, and Integration”


Quality Is Evolving

For decades, pharmaceutical quality functions have often been viewed primarily as guardians of compliance. While these responsibilities remain critical, today’s environment demands something more and that role is changing.

Modern pharmaceutical organizations are operating in increasingly complex environments characterized by advanced therapies, digitalization, artificial intelligence, supply chain challenges, and evolving regulatory expectations.

In this environment, quality can no longer operate solely as a gatekeeper of compliance. Quality must become a strategic integrator. It must connect:

  • People and technology
  • Knowledge and decision-making
  • Compliance and innovation
  • Risk management and continuous improvement
  • Leadership and operational execution

This concept was explored through the lens of Quality 5.0, a framework that positions quality as a human-centric discipline focused on creating meaningful integration across organizations.

As discussed by Natalia Vtyurina, Founder and Chair of the ISPE the Netherlands Quality CoP during the event:

Progress isn’t about making more technology. It’s about making meaningful technology.

Technology alone will not solve our challenges. The future of pharmaceutical quality will be shaped by organizations that successfully connect people, knowledge, culture, decision-making and are able to collaborate across organizational boundaries.

During her talk Vtyurina introduced Quality Transformation 5.0 and elaborated on how to create collaborative workspaces where leadership, human resources, works councils, and quality teams work together to shape the future of the organizations allowing them to stay competitive on the fast-changing market.

This reinforces an important principle:

Quality excellence is achieved when people, knowledge, culture, and leadership come together to make the right decisions for patients, products, and organizations.

Making Quality Easy

Another perspective explored by Ali Amghar, Board Member ISPE Netherlands Quality CoP during the event was the importance of designing systems that naturally guide people toward the right decisions.

Quality professionals often focus on training, procedures, and oversight mechanisms. While these measures remain important, organizations can sometimes overlook a fundamental principle: People naturally follow the path of least resistance. The concept of Poka-Yoke, an error-proofing approach originally developed in manufacturing, offers an alternative.

Rather than relying solely on human vigilance, organizations can design processes that make errors difficult and correct actions intuitive. This principle extends beyond manufacturing and applies equally to quality systems, digital workflows, documentation processes, and operational decision-making.

The highlight:

The most effective tools are the ones you don’t need to think about.

Figure 3. Interplay between behavior, culture and systems–keys toward efficient quality.


Quality becomes stronger when systems are designed to support desired behaviors rather than requiring individuals to constantly overcome obstacles.

Knowledge as a Strategic Asset

One of the strongest themes emerging from the discussions was the growing importance of integrating knowledge management (KM) and quality risk management (QRM) presented by Manouk Tchkrtchian, Co-Chair ISPE Netherlands Quality CoP.

Figure 4. Integrated Quality Approach.


ICH Q10 identifies KM as a key enabler of an effective Pharmaceutical Quality System, yet many organizations still struggle to capture, retain, access, and reuse critical knowledge. Knowledge should be managed as a valuable organizational asset, with defined processes for its creation, review, storage, accessibility, transfer, application, and reuse throughout its lifecycle. Capturing knowledge alone is not enough—it must remain accessible to the right people at the right time so it can continue creating value for the organization.

KM and QRM are closely interconnected. Every risk assessment generates new knowledge, while every piece of knowledge influences future risk assessments. As experienced employees retire, change roles, or leave the organization, valuable expertise can be lost unless effective mechanisms are in place to capture, transfer, and preserve both explicit and tacit knowledge.

Organizations that successfully manage knowledge as a strategic asset are better positioned to:

  • Reduce knowledge loss
  • Improve decision-making
  • Strengthen process understanding
  • Support continual improvement
  • Enhance organizational learning

A particularly important challenge facing the pharmaceutical industry is the retention of tacit knowledge. As highlighted during the seminar:

Capture knowledge today, or risk losing it tomorrow.

Equally important is ensuring that captured knowledge remains accessible, reusable, and continuously enriched throughout its lifecycle so it can support future decisions, innovation, and organizational learning. This principle applies equally to organizations and professional networks, where sharing knowledge across disciplines strengthens both individual expertise and collective capability.

KM Assessment

During and after the event, attendees had the opportunity to complete a questionnaire to assess the maturity of their KM system. Overall, the results show a low level of KM maturity (average scores ranging from 2.1 to 2.7 out of 5, based on 15 respondents). Most respondents indicated that KM processes are informal, ownership is unclear, monitoring is limited, and knowledge retention is not systematically managed. The strongest areas were product/process knowledge management and system integration, although these were also assessed as being at an early stage of development. Overall, the results suggest that while a foundation for KM exists, significant improvement is needed in governance, ownership, and continuous improvement practices.

Breaking Silos Starts with Conversations

One of the central themes discussed during our launch seminar was the importance of breaking down silos. This may sound like a familiar objective, yet many organizations continue to struggle with it.

During interactive discussions led by Gurpal Singh, Board Member ISPE Netherlands Quality CoP involving uality professionals, SMEs, and leaders, participants repeatedly emphasized the same challenge:

  • Critical decisions are rarely made by one function alone.
  • Effective decision-making requires multiple perspectives.
  • Quality professionals bring regulatory and risk-based thinking.
  • SMEs contribute technical and scientific expertise.
  • Operations teams provide practical implementation knowledge.
  • Leadership ensures strategic alignment.

Figure 5. Communication triangle and key enablers of quality culture.


When these perspectives remain disconnected, organizations increase the likelihood of misunderstandings, delays, and unintended risks. When they are integrated, better decisions emerge.

One key observation from our discussions was that participants consistently favored collaborative, structured decision-making approaches over quick operational shortcuts when faced with quality-related dilemmas.

Culture Matters

Perhaps the most important insight from the launch event was that quality culture cannot be created through procedures alone. Organizations can have excellent systems, detailed processes, and comprehensive training programs.

Yet sustainable quality performance ultimately depends on behavior. Participants in our quality culture survey reported strong levels of peer support and willingness to raise concerns. At the same time, opportunities were identified to strengthen leadership visibility and improve communication of organizational priorities.

This finding reflects a broader reality across the industry.

Quality culture is built through daily interactions, trust, transparency, and leadership behaviors. People need to understand not only what decisions are made, but why they are made. In many ways, culture becomes the bridge between compliance and performance.

Henry Ford was an early manufacturing leader whose thinking aligns with today’s quality culture principles. His famous quote: “Quality means doing it right when no one is looking.” Remains relevant in workplaces, businesses, education, and daily life.

Building Communities for the Future

The launch of the ISPE Netherlands Quality CoP is just the beginning. The regional CoP’s ambition extends beyond a single Affiliate or country. No single organization has all the answers. No single function owns quality. The challenges facing pharmaceutical quality today—advanced therapies, digital transformation, AI adoption, knowledge retention, workforce development, and quality culture—are shared across the global industry and require collective learning and shared responsibility. They cannot be solved by individual organizations or functions working in isolation.

CoPs provide a different model. As the industry continues to evolve, the need for such communities will only increase. They create trusted environments where professionals exchange knowledge, challenge assumptions, learn from one another, and collectively accelerate innovation. In doing so, knowledge becomes less dependent on individuals and more embedded within the profession itself.

This vision is already beginning to take shape. In September 2026, representatives from multiple ISPE European Affiliates came together for the first European Quality Communities of Practice Meeting, marking the start of a growing network dedicated to connecting quality professionals across Europe, sharing best practices, and strengthening pharmaceutical quality together.

When we bring together diverse expertise, perspectives, and experiences, quality becomes more than compliance—it becomes a shared capability that drives innovation, resilience, and patient safety. That is why our guiding principle is simple: quality unites.

Learn more about the ISPE Netherlands Affiliate

来源:ISPE iSpeak 专家博客 · ispe.org